Insider Transactions in Q1 2026 at Mirum Pharmaceuticals, Inc. (MIRM)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2026
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6,831
-3.88%
|
$655,776
$96.19 P/Share
|
|
Jan 26
2026
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
842
-18.54%
|
$80,832
$96.19 P/Share
|
|
Jan 26
2026
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
3,143
-11.89%
|
$301,728
$96.19 P/Share
|
|
Jan 26
2026
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,053
-2.35%
|
$101,088
$96.19 P/Share
|
|
Jan 23
2026
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.62%
|
-
|
|
Jan 23
2026
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+24.83%
|
-
|
|
Jan 23
2026
|
Peter Radovich PRESIDENT AND COO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+17.87%
|
-
|
|
Jan 23
2026
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+5.62%
|
-
|
|
Jan 23
2026
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
131,425
+22.26%
|
$8,936,900
$68.48 P/Share
|
|
Jan 23
2026
|
Patrick J Heron |
BUY
Other acquisition or disposition
|
Indirect |
159,277
+32.72%
|
-
|
|
Jan 22
2026
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,098
-4.16%
|
$660,114
$93.33 P/Share
|
|
Jan 22
2026
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
2,382
-10.33%
|
$221,526
$93.33 P/Share
|
|
Jan 22
2026
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,421
-3.26%
|
$132,153
$93.33 P/Share
|
|
Jan 22
2026
|
Joanne Quan CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,822
-12.45%
|
$169,446
$93.33 P/Share
|
|
Jan 22
2026
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
926
-23.34%
|
$86,118
$93.33 P/Share
|
|
Jan 21
2026
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,797
+6.97%
|
-
|
|
Jan 21
2026
|
Peter Radovich PRESIDENT AND COO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,167
+15.3%
|
-
|
|
Jan 21
2026
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+7.11%
|
-
|
|
Jan 21
2026
|
Joanne Quan CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+18.55%
|
-
|
|
Jan 21
2026
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,542
+27.99%
|
-
|
|
Jan 20
2026
|
Joanne Quan CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,911
-37.94%
|
$621,990
$90.27 P/Share
|
|
Jan 16
2026
|
Joanne Quan CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+40.7%
|
-
|
|
Jan 15
2026
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$180,000
$90.99 P/Share
|
|
Jan 15
2026
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$46,000
$23.51 P/Share
|